APRETUDE, long-acting injectable PrEP for HIV-1–negative at-risk adults & adolescents weighing at least 77 lbs. See Prescribing Info & Boxed Warning.
APRETUDE, long-acting injectable PrEP for HIV-1–negative at-risk adults & adolescents weighing at least 77 lbs. See Prescribing Info & Boxed Warning.
原文出处：ViiV Healthcare initiates rolling submission of new drug application with US FDA for long-acting cabotegravir for prevention of HIV 注：以上资讯来源于网络，由香港济民药业整理编辑（如有错漏，请帮忙指正），只为提供全球最新上市药品的资讯，帮助中国患者了解国际新药动态，仅供医护人员内部讨论，不...
除了治疗HIV感染,卡博特韦也被研究用于预防HIV传播,特别是在高危人群中进行长效预防性抗逆转录病毒治疗(Long-Acting Pre-exposure Prophylaxis,LAPR)。预防性抗逆转录病毒治疗是一种预防性措施,用于降低高危人群感染HIV的风险。 LAPR使用的卡博特韦是通过长效注射的形式给予的。长效注射的卡博特韦可以在体内持续释放,提供...
ViiV Healthcare公司12月20日宣布,美国食品和药物管理局 (FDA) 批准了Apreude(cabotegravir,卡博特韦缓释注射悬浮液),这是首个PrEP的长效注射剂,用于有性行为感染 HIV 的风险,并且在开始前 HIV-1 检测呈阴性,体重至少 35 公斤的成人和青少年,用于降低性感染 HIV-1 的风险。
如果获得批准,这款每2个月给药一次的长效注射剂(CAB LA)有潜力改变预防HIV的游戏规则,将给药频率从每年365次口服减少到每年6次注射。 原文出处:ViiV Healthcare receives FDA Breakthrough Therapy Designation for investigational, long-acting cabotegravir for HIV prevention 以上是关于(美国FDA授予cabotegravir突破...
ViiV Healthcare计划在今年年底前开始向全球监管机构提交监管文件,并将最初的提交重点放在开展HPTN 083和HPTN 084临床试验的国家。 原文出处:ViiV Healthcare initiates rolling submission of new drug application with US FDA for long-acting cabotegravir for prevention of HIV...
原文出处:ViiV Healthcare initiates rolling submission of new drug application with US FDA for long-acting cabotegravir for prevention of HIV 注:以上资讯来源于网络,由香港济民药业整理编辑(如有错漏,请帮忙指正),只为提供全球最新上市药品的资讯,帮助中国患者了解国际新药动态,仅供医护人员内部讨论,不作任何...
A long-acting injectable formulation of the HIV integrase inhibitor cabotegravir (CAB-LA) is currently in clinical development for PrEP. Although the long plasma half-life of CAB-LA is an important attribute for PrEP, it also raises concerns about drug resistance emergence if someone becomes infe...
信息来源:Phase 1 Study of Cabotegravir Long-Acting Injectable Formulations Supports ≥4-Monthly Dose Interval Viiv healthcare presents phase i clinical trial findings of a cabotegravir long-acting injectable investigational formulation allowing at least four months between doses 编译:松鼠哥 ...